Switch theme
Sign up to access all valuation multiples
AprilBio Co Ltd is a bio company is developing biologis. It owns long acting protein medicine platform technology utilizing human FAB antobody parts that makes unusual combination to serum akbumin and EX 12 helper phase antibody library technology.
2013
26
LTM Revenue $16.9M
LTM EBITDA $9.2M
$152M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AprilBio has a last 12-month revenue of $16.9M and a last 12-month EBITDA of $9.2M.
In the most recent fiscal year, AprilBio achieved revenue of $18.7M and an EBITDA of $15.1M.
AprilBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AprilBio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $18.7M | XXX | XXX | XXX |
| Gross Profit | $0.1M | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$8.5M | $15.1M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | 80% | XXX | XXX | XXX |
| Net Profit | -$6.1M | -$9.6M | XXX | XXX | XXX |
| Net Margin | NaN% | -51% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, AprilBio's stock price is KRW 14320 (or $10).
AprilBio has current market cap of KRW 314B (or $214M), and EV of KRW 222B (or $152M).
See AprilBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $152M | $214M | XXX | XXX | XXX | XXX | $0.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, AprilBio has market cap of $214M and EV of $152M.
AprilBio's trades at 9.0x LTM EV/Revenue multiple, and 16.4x LTM EBITDA.
Analysts estimate AprilBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for AprilBio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $152M | XXX | XXX | XXX |
| EV/Revenue | 8.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | XXX | XXX |
| P/E | 15.7x | XXX | XXX | XXX |
| P/E/Growth | -6.2x | XXX | XXX | XXX |
| EV/FCF | 10.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAprilBio's NTM/LTM revenue growth is -13%
AprilBio's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, AprilBio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate AprilBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for AprilBio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | 80% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -277% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 67% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AprilBio acquired XXX companies to date.
Last acquisition by AprilBio was XXXXXXXX, XXXXX XXXXX XXXXXX . AprilBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was AprilBio founded? | AprilBio was founded in 2013. |
| Where is AprilBio headquartered? | AprilBio is headquartered in South Korea. |
| How many employees does AprilBio have? | As of today, AprilBio has 26 employees. |
| Is AprilBio publicy listed? | Yes, AprilBio is a public company listed on KRX. |
| What is the stock symbol of AprilBio? | AprilBio trades under 397030 ticker. |
| When did AprilBio go public? | AprilBio went public in 2022. |
| Who are competitors of AprilBio? | Similar companies to AprilBio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AprilBio? | AprilBio's current market cap is $214M |
| What is the current revenue of AprilBio? | AprilBio's last 12-month revenue is $16.9M. |
| What is the current EBITDA of AprilBio? | AprilBio's last 12-month EBITDA is $9.2M. |
| What is the current EV/Revenue multiple of AprilBio? | Current revenue multiple of AprilBio is 9.0x. |
| What is the current EV/EBITDA multiple of AprilBio? | Current EBITDA multiple of AprilBio is 16.4x. |
| Is AprilBio profitable? | Yes, AprilBio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
